Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Alembic Pharmaceutical launches Desvenlafaxine in US: Angel Broking

Posted On: 2017-03-04 23:57:05

Views of Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking):

"Breckenridge Pharmaceutical, Inc. and Alembic Pharmaceuticals Limited have launched their ANDA desvenlafaxine succinate extended-release tablets 50mg and 100mg, a generic version of Pristiq® by Pfizer Inc. Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers (expected to be around 5-6). Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge. The Paragraph IV litigation with respect to the ANDA has been settled on terms that are confidential. The settlement includes a license effective prior to the expirations of the patents involved in the litigation.

Desvenlafaxine is a prescription drug that is indicated for the treatment of major depressive disorder. Desvenlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Pristiq® generated sales of US$883mn, based on December 2016 IMS Health Sales Data. The product will be available in 50mg and 100mg tablets. Thus given the competition we expect the company to gross around US$25mn and US$8mn, of net sales and profit respectively, during the 6-month exclusivity. We upgrade the rating to BUY with a revised price of INR 689."

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.602.6 as compared to the previous close of Rs. 596.75. The total number of shares traded during the day was 15853 in over 863 trades.

The stock hit an intraday high of Rs. 615 and intraday low of 600. The net turnover during the day was Rs. 9624053.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Banks : Where is capital consumption in public banks? : Deep dive into capital consumption and requirements - Kotak
The Pitch Report - Result Update: Karnataka Bank Ltd - BUY - TP Rs.220 - Kotak
Chhota (to) MOTA ideas: Venky's (india) Ltd - REDUCE - TP Rs.2200 - Kotak
Bajaj Corp - GST impacts reported results; Retail growth encouraging though - JM Financial
Hatsun Agro Ltd - Result Update - Q1FY18 - KR Choksey
Views on Infosys Limited 1QFY2018 Results: Angel Broking
The Pitch Report: Sutlej Textiles - BUY - TP Rs.1220 - Kotak
Result Update : Cyient Ltd (Cyient) - REDUCE - TP Rs.521 - Kotak
Company Visit Note : Shankara Building Products Ltd - Kotak
Views on Tata Consultancy Services Limited 1QFY2018 Results: Angel Broking
Economy: Inflation comfort to prompt a rate cut - Kotak
Petroleum consumption grows 0.4% in June after growing 3-5% in April and May
Energy-petroleum consumption: Slow and unsteady - Kotak
Metals & Mining (Attractive): 1QFY18-a tad weak due to lower prices, one-offs - Kotak
HPCL may finally become an arm of upstream ONGC: Angel Broking
Economy: FX outlook: No radical turning of tide - Kotak
Company Visit Note: Rajoo Engineers Ltd (REL) - NOT RATED - Kotak
Infrastructure: LPG - at the forefront of growth - Kotak
Banks : Marginal improvement - Annual report analysis on NPLs, restructured loans and others - Kotak
Energy: 1QFY18E preview-weak for OMCs and RIL; strong for CGDs - Kotak
Company Visit Note: Ion Exchange Ltd - NOT RATED - Kotak
L&T Finance Holdings Ltd - Prudent downsizing for attractive business revival: Angel Broking
Sector Update: INNERWEAR SECTOR REPORT - Kotak
Syngene International - Setting the stage for capacity driven growth: Angel Broking
Management Meet Update: Bhansali Engineering Polymers Ltd - NOT RATED - Kotak
Company Update: Gujarat Pipavav Port Ltd - BUY - TP Rs.180 - Kotak
Lupin - Launches MoxiFloxacin HCL Opthalmic Solution in US: Angel Broking
Tepid growth as buyers delay purchase decision ahead of GST - CSEC Research
Auto Industry Volume Update: June 2017 - Kotak
Automobile June Sales subdued, GST led price cuts to benefit the sector: Angel Broking
Technology: 1QFY18E Preview - Kotak
Banks : Retail loan growth: the only game in town - Kotak
GST: A Khatta-Meetha blend to drive long term economic growth: Angel Broking
Views On GST Roll Out - Zerodha
Company Update: Blue Dart Express (BDE) - BUY - TP Rs.5150 - Kotak
Metals & Mining (Attractive): Aluminum pricing - the bull and the bear of it - Kotak
Technology: Another tough year for Indian IT - Kotak
CHHOTA (to) MOTA ideas: Venky's (India) Ltd - BUY - TP Rs.2150 - Kotak
Company Update: CG Power and Industrial Solution Ltd (CG) - ACCUMULATE - TP Rs.84 - Kotak
Supreme Industries - Visit Note - Plastic Industry Juggernaut - Nirmal Bang
Crompton Greaves Consumer Electricals - Initiating Coverage - Rechristened For An Electrifying Future - Nirmal Bang
AU Small Finance Bank - IPO Update - Unique Positioning - Nirmal Bang
AU Small Finance Bank Ltd - IPO Note - Angel Broking
Company Visit Note: Maithan Alloys Ltd. (MAL) - NOT RATED - Kotak
Economy/Strategy: GST: Godot has arrived - Kotak
The Pitch Report: Karnataka Bank Ltd - BUY - TP Rs.220 - Kotak
Company Update: Voltas Ltd - ACCUMULATE - TP Rs.500 - Kotak
Technology: Accenture-tightens revenue growth guidance band - Kotak
Metals & Mining (Attractive): India Steel-on a recovery path - Kotak
Nasscom guides for 7-8% growth, lower than 8.6% in c/c of FY2017 - Kotak


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017